Open AccessA Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids
Author(s) -
Jan Wysocki,
Minghao Ye,
Luise Hassler,
Ashwani Gupta,
Yuguo Wang,
Vlad Nicoleascu,
Glenn Randall,
Jason A. Wertheim,
Daniel Batlle
Publication year - 2021
Publication title -
journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.451
H-Index - 279
eISSN - 1533-3450
pISSN - 1046-6673
DOI - 10.1681/asn.2020101537
Subject(s) - covid-19 , kidney , decoy , virology , organoid , enzyme , medicine , pharmacology , chemistry , biology , microbiology and biotechnology , biochemistry , receptor , outbreak , disease , infectious disease (medical specialty)
There is an urgent need for approaches to prevent and treat SARS-CoV-2 infection. Administration of soluble ACE2 protein acting as a decoy to bind to SARS-CoV-2 should limit viral uptake mediated by binding to membrane-bound full-length ACE2, and further therapeutic benefit should result from ensuring enzymatic ACE2 activity to affected organs in patients with COVID-19.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom